<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161599</url>
  </required_header>
  <id_info>
    <org_study_id>2019-004283-21</org_study_id>
    <nct_id>NCT04161599</nct_id>
  </id_info>
  <brief_title>Preoperative Oral Antibiotics With vs Without Mechanical Bowel Preparation to Reduce Surgical Site Infections Following Colonic Resection: an International Randomized Controlled Trial.</brief_title>
  <acronym>ORALEV2</acronym>
  <official_title>Oral + Parenteral Antibiotic Prophylaxis Before Colonic Surgery With vs Without Mechanical Bowel Preparation: a Prospective, Multicentric, Randomised, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ORALEV Study found that preoperative oral antibiotics can reduce the incidence of&#xD;
      surgical site infections after colonic resection, compared with no preparation.&#xD;
&#xD;
      The role of mechanical bowel preparation in patients needing colonic surgery is yet to be&#xD;
      elucidated.&#xD;
&#xD;
      No randomised controlled trials have assessed the impact of mechanical bowel preparation&#xD;
      combined with oral antibiotics on the incidence of surgical site infections after colonic&#xD;
      surgery, compared with oral antibiotics only.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      International, multicentre, pragmatic, parallel-group, randomised controlled trial.&#xD;
&#xD;
      Routine antibiotics for the intravenous and oral prophylaxis of colorectal surgery will be&#xD;
      used.&#xD;
&#xD;
      Experimental group: Patients undergoing elective colonic surgery that involves colonic&#xD;
      resection.&#xD;
&#xD;
      The antibiotic prophylaxis in this group will be composed of:&#xD;
&#xD;
      An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) and metronidazole (250mg /&#xD;
      8h, 3 doses) the day before surgery, plus mechanical bowel preparation with Sodium&#xD;
      picosulfate, light magnesium oxide, and anhydrous citric acid (10 mg - 3.5 g - 10.97 g per&#xD;
      dose/ 2 doses the day before surgery) + An intravenous antibiotics pattern of cefuroxime 1,5&#xD;
      g and metronidazole 1 g at anesthetic induction.&#xD;
&#xD;
      Control group: Patients undergoing elective colonic surgery that involves colonic resection.&#xD;
&#xD;
      The antibiotic prophylaxis in this group will be composed of:&#xD;
&#xD;
      An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) and metronidazole (250mg /&#xD;
      8h, 3 doses)&#xD;
&#xD;
      + An intravenous antibiotic pattern of cefuroxime 1,5 g and metronidazole 1 gr at anesthetic&#xD;
      induction.&#xD;
&#xD;
      In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the&#xD;
      intraoperative time prolongs for more than three hours or if there is an intraoperative&#xD;
      bleeding over 1000cc.&#xD;
&#xD;
      There will not be a placebo treatment. Subject compliance will be evaluated according to the&#xD;
      usual practice in surgical care field&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 14, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Wound infection</measure>
    <time_frame>30 days</time_frame>
    <description>Superficial, deep, body-cavity This is a Clinical measure supported by image if necessary All the morbidity problems are reported independently</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Hematoma, seroma, evisceration&#xD;
This is a Clinical measure. This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impaired healing</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>This is a Clinical measure always supported by image tests. This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occlusive problems</measure>
    <time_frame>30 days from surgery</time_frame>
    <description>Intestinal occlusion, Anastomotic stenosis, Postoperative ileus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nephro-urinary complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Acute urinary retention, Acute renal failure, cystitis, pyelonephritis ...&#xD;
This is a Clinical measure supported by more specific tests if necessary. This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to drugs (Harms)</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Any adverse event related with the drug&#xD;
•This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete recovery</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Interval between hospital admission and complete recovery (&quot;can be discharged&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 7 days</time_frame>
    <description>Hospital stay since colorectal surgery is done</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iatrogenic problems</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Injury to structures such as ureters, bowel loops artery / veins .&#xD;
•This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding problems</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Hemoperitoneum, abdominal hematoma,anastomotic bleeding&#xD;
•This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Acute myocardial infarction, angor pectoris , atrial fibrillation, acute pulmonary edema&#xD;
This is a Clinical measure supported by more specific tests if necessary. This morbidity problems are reported independently as a YES/NO variable Cardiologist report will be required for including this items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Pneumonia, Atelectasia, Pulmonary embolism, ARDS&#xD;
This is a Clinical measure always supported by image . This morbidity problems are reported independently as a YES/NO variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Disorientation, cerebral vascular accident,&#xD;
This is a Clinical measure. This morbidity problems are reported independently as a YES/NO variable. Neurologist report will be required beyond disorientation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative intestinal problems</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Postoperative diarrhoea, nausea and vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Need to be readmitted after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reintervention</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Need to be reoperated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Hypovolemia</measure>
    <time_frame>Intraoperative assessment</time_frame>
    <description>Signs or symptoms of hypovolemia not related with bleeding, as assessed by the anesthetist at surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with preparation received</measure>
    <time_frame>within the 30 days from surgery</time_frame>
    <description>Patient satisfaction with the preparation receivced, assessed with a Verbal Rating Scale (VRS) from 1 (minimum satisfaction) to 10 (maximum satisfaction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Patient death for any cause and patient death in relation with treatment received</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anastomotic leak</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>clinical, radiological or intraoperatively detected abdominal or pelvic leak or collection</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Complications at 60 days of follow up</measure>
    <time_frame>60 days after surgery</time_frame>
    <description>Complications and events will be recorded at 60-day follow-up, including:&#xD;
Primary Outcome Measure, Outcome 1: Rate of Wound infection&#xD;
Secondary Outcome Measures: Outcomes 2-6 / Outcomes 9-16 / Outcome 19</description>
  </other_outcome>
  <other_outcome>
    <measure>Complications at 5 years of follow up</measure>
    <time_frame>5 years after surgery</time_frame>
    <description>Complications and events will be recorded at 5-year follow-up, including:&#xD;
Primary Outcome Measure, Outcome 1: Rate of Wound infection&#xD;
Secondary Outcome Measures: Outcomes 2-6 / Outcomes 9-16 / Outcome 19&#xD;
Readmission related with infections, with culture and antibiogram.&#xD;
In patients with cancer, the following variables will also be collected: Local recurrence / Systemic recurrence</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">968</enrollment>
  <condition>Wounds and Injuries</condition>
  <condition>Surgery--Complications</condition>
  <arm_group>
    <arm_group_label>Oral + Parenteral prophylaxis + Mechanical Bowel Preparation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Extra dosage - cefuroxime (750mg) I.V&#xD;
Procedure: Colonic Surgery Both groups undergo colonic surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)&#xD;
Drug: Cefuroxime 750mg oral An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.&#xD;
Drug: Metronidazole 250mg oral An oral antibiotic pattern of metronidazole (250mg / 8h, 3 doses) the day before surgery.&#xD;
Drug: Sodium picosulfate, magnesium oxide, citric acid anhydrous 15.08 g oral An oral laxative for bowel cleansing (2 doses) the day before surgery.&#xD;
Drug: Metronidazole 1 g Intravenous An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.&#xD;
Drug: Cefuroxime 1,5 g Intravenous An intravenous antibiotic pattern of cefuroxime 1,5 g during anesthetic induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral + Parenteral prophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Extra dosage - cefuroxime (750mg) I.V In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc&#xD;
Procedure: Colonic Surgery Both groups undergo colonic surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)&#xD;
Drug: Cefuroxime 750mg oral An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.&#xD;
Drug: Metronidazole 250mg oral An oral antibiotic pattern of metronidazole (250mg / 8h, 3 doses) the day before surgery.&#xD;
Drug: Metronidazole 1 gr Intravenous An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.&#xD;
Drug: Cefuroxime 1,5 g Intravenous An intravenous antibiotic pattern of cefuroxime 1,5 g during anesthetic induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefuroxime (750mg) I.V</intervention_name>
    <description>Extra dosage</description>
    <arm_group_label>Oral + Parenteral prophylaxis</arm_group_label>
    <arm_group_label>Oral + Parenteral prophylaxis + Mechanical Bowel Preparation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colonic Surgery</intervention_name>
    <description>Colonic Surgery</description>
    <arm_group_label>Oral + Parenteral prophylaxis</arm_group_label>
    <arm_group_label>Oral + Parenteral prophylaxis + Mechanical Bowel Preparation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefuroxime 750mg oral</intervention_name>
    <description>Oral prophylaxis</description>
    <arm_group_label>Oral + Parenteral prophylaxis</arm_group_label>
    <arm_group_label>Oral + Parenteral prophylaxis + Mechanical Bowel Preparation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole 250 MG Oral Tablet [Flagyl]</intervention_name>
    <description>Oral prophylaxis</description>
    <arm_group_label>Oral + Parenteral prophylaxis</arm_group_label>
    <arm_group_label>Oral + Parenteral prophylaxis + Mechanical Bowel Preparation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole 1 g Intravenous</intervention_name>
    <description>IV prophylaxis</description>
    <arm_group_label>Oral + Parenteral prophylaxis</arm_group_label>
    <arm_group_label>Oral + Parenteral prophylaxis + Mechanical Bowel Preparation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefuroxime 1,5 g Intravenous</intervention_name>
    <description>IV prophylaxis</description>
    <arm_group_label>Oral + Parenteral prophylaxis</arm_group_label>
    <arm_group_label>Oral + Parenteral prophylaxis + Mechanical Bowel Preparation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium picosulfate, light magnesium oxide, anhydrous citric acid 10 mg/3.5 g/10.97 g Oral</intervention_name>
    <description>Laxative for bowel cleansing</description>
    <arm_group_label>Oral + Parenteral prophylaxis + Mechanical Bowel Preparation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of both genders, aged 18 years or above, with colonic disease without&#xD;
             contraindications to surgical treatment, diagnosed with neoplasia or diverticular&#xD;
             disease (diverticulosis with indication to elective surgery: stricture, chronic&#xD;
             constipation), patients for whom a segmental or total colectomy is indicated.&#xD;
&#xD;
          -  Patients who voluntarily accept to join the study and sign a dedicated written&#xD;
             consent.&#xD;
&#xD;
          -  Capability of understanding the study and take the medications prescribed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing urgent surgery or no elective admission&#xD;
&#xD;
          -  Patients who refuse to participate&#xD;
&#xD;
          -  Patients with rectal disease or neoplasia&#xD;
&#xD;
          -  Patients with pre-existing intrabdominal sepsis (abscess, acute diverticulitis)&#xD;
&#xD;
          -  Patients who received preoperative antibiotic treatment for any other reasons during&#xD;
             the two weeks before surgery&#xD;
&#xD;
          -  Patients with Crohn's disease or ulcerative colitis&#xD;
&#xD;
          -  Patients unlikely to adhere to the treatment prescribed&#xD;
&#xD;
          -  Patients with allergy or contraindication to the medications used in the study&#xD;
&#xD;
          -  Patients who need mechanical bowel preparation&#xD;
&#xD;
          -  Patients with contraindication to bowel preparation used in the study (Citrafleet®):&#xD;
&#xD;
          -  Patients with kidney failure needing haemodialysis or with hypermagnesemia&#xD;
&#xD;
          -  Patients with severe heart failure&#xD;
&#xD;
          -  Patients with gastric or duodenal ulcer&#xD;
&#xD;
          -  Patients with mechanical obstruction&#xD;
&#xD;
          -  Patients with toxic megacolon&#xD;
&#xD;
          -  Patients with ascites or rhabdomyolysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eloy Espín-Basany, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Valle de Hebron, Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianluca Pellino, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Valle de Hebron, Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandro Solís-Peña, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Valle de Hebron, Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eloy Espín-Basany, MD PhD</last_name>
    <phone>934 893 000</phone>
    <phone_ext>6587</phone_ext>
    <email>eespin@vhebron.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gianluca Pellino, MD, PhD</last_name>
    <phone>934 893 000</phone>
    <phone_ext>6587</phone_ext>
    <email>gpellino@vhebron.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General University Hospital of Patras</name>
      <address>
        <city>Patra</city>
        <country>Greece</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesck Mulita</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonino Spinelli</last_name>
    </contact>
    <contact_backup>
      <last_name>Annalisa Maroli</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tomsk Oncological Hospital</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Eugeniy Drozdov</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona, Spain</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Eloy Espín Basany, MD PhD</last_name>
      <phone>934 893 000</phone>
      <phone_ext>6587</phone_ext>
      <email>eespin@mac.com</email>
    </contact>
    <contact_backup>
      <last_name>María Martínez Lopez, MD</last_name>
      <email>m.martinez.21@vhebron.net</email>
    </contact_backup>
    <investigator>
      <last_name>Gianluca Pellino, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <state>Hospitalet De Llobregat, Barcelona, Spain</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Sebastiano Biondo, MD PhD</last_name>
      <phone>932 607 500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces</name>
      <address>
        <city>Cruces</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>José María García González</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Manuel Muinelo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUV Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Losanna</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabian Grass</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital, Imperial College of London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Christos Kontovounisios</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Pellino G, Solís-Peña A, Kraft M, Huguet BM, Espín-Basany E. Preoperative oral antibiotics with versus without mechanical bowel preparation to reduce surgical site infections following colonic resection: Protocol for an international randomized controlled trial (ORALEV2). Colorectal Dis. 2021 Aug;23(8):2173-2181. doi: 10.1111/codi.15681. Epub 2021 May 12.</citation>
    <PMID>33872448</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>August 28, 2021</last_update_submitted>
  <last_update_submitted_qc>August 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Cefuroxime axetil</mesh_term>
    <mesh_term>Picosulfate sodium</mesh_term>
    <mesh_term>Magnesium Oxide</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sodium Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

